Literature DB >> 15541472

Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.

Massimo Breccia1, Marco Mancini, Mauro Nanni, Gianna Maria D'Elia, Ida Carmosino, Roberto Latagliata, Chiara Sarlo, Franco Mandelli, Giuliana Alimena.   

Abstract

The International Prognostic Scoring System (IPSS) for myelodysplastic syndromes (MDS) has defined patients with a normal karyotype as a good risk cytogenetic subgroup, but nevertheless a fraction of these patients has a poor outcome similar to that of high risk patients. We retrospectively analysed our series of myelodysplastic patients with normal karyotype observed in a period of 11 years, with the aim of identifying clinical features of possible prognostic significance within this subgroup of patients. Multivariate analysis showed that among clinical scoring systems, the Bournemouth score appears the best prognostic indicator for risk of leukemic transformation, and platelet count <100 x 10(9)/l(-1), presence of haemorrhagic symptoms at time of diagnosis and morphologic FAB classification are the main prognostic factors for prediction of survival. In the absence of genetic abnormalities as detected by conventional cytogenetics or even the more sensitive molecular techniques in MDS, clinical variables could be of help in identifying patients with different prognosis, suitable for risk adapted therapeutic strategies.

Entities:  

Mesh:

Year:  2005        PMID: 15541472     DOI: 10.1016/j.leukres.2004.05.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  1 in total

1.  Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD.

Authors:  Xiao Qin Wang; John Ryder; Sherilyn A Gross; Guowei Lin; Richard D Irons
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.